We are live on ! Find out more
SFM

Sphera Funds Management Portfolio holdings

AUM $630M
1-Year Est. Return 108.65%
This Fund
S&P 500
This Quarter Est. Return
+10.32%
1 Year Est. Return
+108.65%
3 Year Est. Return
+217.64%
5 Year Est. Return
+342.91%
10 Year Est. Return
+2,254.45%
AUM
$871M
AUM Growth
+$146M
Cap. Flow
+$118M
Cap. Flow %
13.5%
Top 10 Hldgs %
47.29%
Holding
141
New
32
Increased
44
Reduced
18
Closed
28

Top Buys

Rank Stock Value
1
JNJ icon
Johnson & Johnson
JNJ
+$43.2M
2
BMY icon
Bristol-Myers Squibb
BMY
+$32M
3
VTRS icon
Viatris
VTRS
+$17.7M
4
ARGX icon
argenx
ARGX
+$12.1M
5
IMMU
Immunomedics Inc
IMMU
+$9.29M

Top Sells

Rank Stock Value
1
SHPG
Shire pic
SHPG
+$21.4M
2
AMGN icon
Amgen
AMGN
+$18.5M
3
ALNY icon
Alnylam Pharmaceuticals
ALNY
+$15.6M
4
BIIB icon
Biogen
BIIB
+$14.5M
5
PFE icon
Pfizer
PFE
+$14.1M

Sector Composition

Rank Sector Weight
1 Healthcare 75.17%
2 Technology 4.8%
3 Industrials 2.36%
4 Financials 1.58%
5 Materials 0.58%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
XBI icon
1
PUT
State Street SPDR S&P Biotech ETF
XBI
$9.95B
$105M 12.11%
+1,100,000
New +$107M
MRK icon
2
Merck
MRK
$322B
$55.3M 6.35%
817,440
+104,800
+15% +$6.68M
VTRS icon
3
Viatris
VTRS
$20.4B
$48.5M 5.57%
1,325,000
+471,000
+55% +$17.7M
JNJ icon
4
Johnson & Johnson
JNJ
$618B
$44.9M 5.16%
+325,000
New +$43.2M
GSK icon
5
GSK
GSK
$104B
$34.7M 3.99%
692,000
+80,000
+13% +$4.06M
BMY icon
6
Bristol-Myers Squibb
BMY
$133B
$33.5M 3.85%
+540,000
New +$32M
GILD icon
7
Gilead Sciences
GILD
$162B
$32.4M 3.72%
420,000
+65,000
+18% +$4.91M
FOLD
8
DELISTED
Amicus Therapeutics
FOLD
$21.6M 2.48%
1,787,994
+598,938
+50% +$8.38M
ALXN
9
DELISTED
Alexion Pharmaceuticals
ALXN
$19.7M 2.26%
141,700
-18,844
-12% -$2.36M
ALDX icon
10
Aldeyra Therapeutics
ALDX
$92.9M
$15.8M 1.81%
1,142,089
+295,154
+35% +$2.39M
VKTX icon
11
Viking Therapeutics
VKTX
$3.7B
$15M 1.72%
859,727
+77,303
+10% +$920K
IMMU
12
DELISTED
Immunomedics Inc
IMMU
$14.6M 1.67%
699,039
+392,384
+128% +$9.29M
CLLS
13
Cellectis
CLLS
$277M
$12.6M 1.45%
447,970
+96,096
+27% +$2.76M
SRPT icon
14
Sarepta Therapeutics
SRPT
$1.57B
$12.3M 1.41%
76,116
-68,980
-48% -$9.43M
BLUE
15
DELISTED
bluebird bio
BLUE
$11.4M 1.31%
6,052
+456
+8% +$942K
ARQL
16
DELISTED
Arqule Inc
ARQL
$11.3M 1.3%
2,005,243
+507,560
+34% +$2.89M
NERV icon
17
Minerva Neurosciences
NERV
$185M
$10.6M 1.21%
105,299
+2,784
+3% +$209K
CSTE icon
18
Caesarstone
CSTE
$72.3M
$10.4M 1.2%
561,311
+330,495
+143% +$5.8M
ARGX icon
19
argenx
ARGX
$53.4B
$10.3M 1.19%
+136,381
New +$12.1M
PTCT icon
20
PTC Therapeutics
PTCT
$5.64B
$9.87M 1.13%
+210,000
New +$8.69M
TVTX icon
21
Travere Therapeutics
TVTX
$5.2B
$9.36M 1.07%
325,678
-27,394
-8% -$783K
AUTL
22
Autolus Therapeutics
AUTL
$397M
$8.94M 1.03%
296,251
+120,206
+68% +$3.24M
BMRN icon
23
BioMarin Pharmaceuticals
BMRN
$11.6B
$8.53M 0.98%
88,000
+81,750
+1,308% +$8.16M
SAGE
24
DELISTED
Sage Therapeutics
SAGE
$8.47M 0.97%
+60,000
New +$9.26M
MSFT icon
25
Microsoft
MSFT
$3.45T
$7.97M 0.91%
69,656
-4,779
-6% -$518K
1
2 3 4 5

Similar funds

VIM
Vancity Investment Management Vancouver, British Columbia, Canada $629M AUM 2.49% 1-Year Est. Return
KCMH
Keywise Capital Management (HK) Hong Kong $630M AUM 81.01% 1-Year Est. Return
FCFC
First Commonwealth Financial Corp Indiana, Pennsylvania $629M AUM 20.47% 1-Year Est. Return
BI
BlueSpruce Investments Chicago, Illinois $631M AUM 11.83% 1-Year Est. Return
PWW
Pettyjohn Wood & White Lynchburg, Virginia $628M AUM 20.96% 1-Year Est. Return
TTSTC
Texas Treasury Safekeeping Trust Company Austin, Texas $628M AUM 15.58% 1-Year Est. Return
SWP
Summit Wealth Partners Orlando, Florida $632M AUM 9.71% 1-Year Est. Return
EIM
Essex Investment Management Boston, Massachusetts $632M AUM 95.36% 1-Year Est. Return

Sphera Funds Management's Q3 2018 Portfolio in Review

As of Q3 2018, Sphera Funds Management held 141 positions worth $871M, up 20% from $725M the previous quarter. Its ten largest holdings account for 47% of the portfolio.

Sphera Funds Management deployed $118M of net new capital in Q3 2018, opening 32 new positions and adding to 44 existing holdings. Its largest new stake was Johnson & Johnson: 325,000 shares worth $44.9M.

By sector, the portfolio is most concentrated in Healthcare at 75% of assets, up from 72% a quarter earlier, followed by Technology and Industrials.

On the sell side, the largest reduction was Alnylam Pharmaceuticals, an estimated $15.6M trimmed.

  • Sphera Funds Management's largest Q3 2018 buy was Johnson & Johnson: 325,000 shares worth $44.9M.
  • Sphera Funds Management added most to Viatris in Q3 2018, an estimated $17.7M increase.
  • Sphera Funds Management's biggest Q3 2018 reduction was Alnylam Pharmaceuticals, cutting an estimated $15.6M.
  • Sphera Funds Management fully exited Shire pic in Q3 2018, selling an estimated $21.4M.
  • Sphera Funds Management's ten largest holdings make up 47% of its $871M portfolio in Q3 2018.
  • Sphera Funds Management opened 32 new positions and closed 28 in Q3 2018.
  • Sphera Funds Management's portfolio value rose 20% quarter-over-quarter to $871M.

Based on Sphera Funds Management's 13F filing for Q3 2018, filed 14 Nov 2018.